Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8<sup>+</sup> T cells

20256 citationsJournal Articlegold Open Access

Authors

Kayoung Shin · GI Innovation (South Korea)

Min Park · GI Innovation (South Korea)

Seoho Kim · GI Innovation (South Korea)

Haejong Lee · GI Innovation (South Korea)

Yuseong Lee · GI Innovation (South Korea)

Jong‐Il Kim · GI Innovation (South Korea)

Suyoun Park ·

Abstract

GI-αCD73/IL-2v bispecific protein is a novel and potent immunocytokine with significant antitumor immunity through cis-binding on CD8<sup>+</sup> T cells.

Topics & Keywords

Adenosine and Purinergic Signaling RNA Interference and Gene Delivery Immune Cell Function and Interaction

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 13, Issue 3, pp. e008594-e008594

DOI: 10.1136/jitc-2023-008594

Field-Weighted Citation Impact: 6.58